Last reviewed · How we verify

Colchicine 0.5mg

Huashan Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Colchicine 0.5mg is a Small molecule drug developed by Huashan Hospital. It is currently FDA-approved.

Colchicine 0.5mg is a small molecule inhibitor of the molecular target tubulin, classified as an inhibitor. It is being studied for various conditions, including gout, atrial fibrillation, and abdominal aortic aneurysm progression.

At a glance

Generic nameColchicine 0.5mg
SponsorHuashan Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Colchicine 0.5mg

What is Colchicine 0.5mg?

Colchicine 0.5mg is a Small molecule drug developed by Huashan Hospital.

Who makes Colchicine 0.5mg?

Colchicine 0.5mg is developed and marketed by Huashan Hospital (see full Huashan Hospital pipeline at /company/huashan-hospital).

What development phase is Colchicine 0.5mg in?

Colchicine 0.5mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing